BACKGROUND: Proteomic approaches allow measurement of thousands of proteins in a single specimen, which can accelerate biomarker discovery. However, applying these technologies to massive biobanks is not currently feasible because of the practical barriers and costs of implementing such assays at scale. To overcome these challenges, we used a "virtual proteomic" approach, linking genetically predicted protein levels to clinical diagnoses in >40 000 individuals.
B
iomarkers can facilitate early detection of disease and suggest potential therapeutic targets. 1 A limitation of traditional biomarker studies is that the selection of candidates is constrained by existing knowledge of biological pathways that contribute to the disease in question. Hence, these markers often add little to the clinical data because they provide overlapping information. 2, 3 Furthermore, such biomarkers may yield few novel insights into the biological mechanisms modulating or driving disease risk. Emerging technologies in metabolomics and proteomics allow the interrogation of large numbers of biomarkers from diverse pathways. The extended range of biomarkers that can be measured in biological specimens has enabled discoveryoriented biomarker methodologies. However, applying these approaches in large cohorts of individuals is typically not feasible because of the practical challenges and resource costs of implementing these assays at scale.
Circulating levels of many biomarkers are modulated by genetic variation that can be identified and quantified with approaches such as the genome-wide interrogation of variability attributable to common single nucleotide polymorphisms (SNPs). Genetic risk scores constructed from these analyses can be used to calculate a genetically predicted biomarker level in a genotyped individual, a so-called virtual biomarker. 4 Because the genetic contribution to many circulating biomarker levels is highly significant, 5 a genetic predictor for each biomarker can be developed from a relatively small number of genotyped individuals and then used to compute genetically predicted biomarker levels in readily available, much larger genotyped populations. Furthermore, this genetically predicted biomarker can be used to test associations with any phenotype measured in the second population. 4 In sum, genetic approaches can tremendously augment the effective sample sizes and the number of phenotypes that can be evaluated for a biomarker.
We hypothesized that we could apply these approaches to identify clinical phenotypes associated with plasma protein levels. We used a data set derived from participants in the FHS (Framingham Heart Study) Offspring cohort who had undergone profiling of 1129 plasma proteins with an aptamer-based proteomic technology. 6, 7 We constructed genetic instruments that were then used to compute genetically predicted protein levels in a large population of participants in the Electronic Medical Records and Genomics (eMERGE) network, a consortium of medical centers with electronic health records (EHRs)-linked DNA biobanks. 8 We used these genetically predicted values to interrogate a broad range of curated phenotypes to identify novel candidate biomarker-disease associations. We then validated 2 especially intriguing associations with atherosclerotic cardiovascular traits for which the directly measured biomarkers were available in a traditional epidemiological cohort. We anticipate that this novel approach will greatly accelerate the application of molecular profiling in clinical and research settings.
METHODS
The data, analytical methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure. Genetic data are available via data deposits made by the eMERGE Network to the database of Genotypes and Phenotypes, 9 and clinical phenotypes can be requested via data use agreements through the eMERGE Network (https://emerge.mc.vanderbilt.edu/). 8 An overview of the study design is shown in Figure 1 .
Study Populations

EHR Populations
The EHR populations (n=41 288) were from the eMERGE Network, a consortium of medical centers using EHRs as a tool for genomic research, and from Vanderbilt University Medical Center's BioVU resource (Table I in the online-only  Data Supplement) . 10 The participating eMERGE sites were the Geisinger Health System, Vanderbilt University Medical Center, the Marshfield Clinic, Northwestern University, Harvard University, the Mayo Clinic, and Kaiser Permanente/ University of Washington, Seattle. All participants were born before 1990 and clustered within 4 SDs of the first 2 principal components based on a subset of individuals self-identified as white, non-Hispanic participants.
Clinical Perspective
What Is New?
• High-throughput proteomic approaches can measure large numbers of proteins, some of which may serve as biomarkers of disease, in human biospecimens.
• Given the practical barriers to conducting largescale proteomic studies, we developed a "virtual biomarker" strategy that leverages genetic data and clinical phenotypes extracted from electronic health records.
• We identified C-type lectin domain family 1 member B and platelet-derived growth factor receptor-β as potential circulating biomarkers of atherosclerosis and validated them in an epidemiological cohort.
What Are the Clinical Implications?
• A virtual biomarker study can efficiently identify potential biomarker-disease associations.
• These associations can subsequently be validated in targeted studies.
• Genetically driven biomarker studies have the potential to accelerate biomarker discovery for a broad range of diseases. 11 is a Swedish population-based, observational cohort used for epidemiological evaluation of selected genetic associations identified in the primary analyses. The MDCS set comprised 651 participants from 2 nested case-control samples (163 cases of incident type 2 diabetes mellitus, 162 cases of incident coronary heart disease, and 326 control subjects; Table II in the online-only Data Supplement). Participants with prevalent coronary heart disease or type 2 diabetes mellitus were excluded.
Genetic Data
SNP genotype data for the EHR populations were acquired on the Illumina Human660W-Quadv1_A, HumanOmni1-Quad, HumanOmni5-Quad, MEGA-EX, Human610, Human550, HumanOmniExpressExome-8v1.2A, and MegArray platforms. Quality control steps for the EHR data sets were performed per previously published protocols. 12 Quality control analyses used PLINK version 1.90β3. 13 SNPs were prephased with SHAPEIT 14 and imputed with IMPUTE2 15 in conjunction with the October 2014 release of the 1000 Genomes cosmopolitan reference haplotypes. Imputed data were filtered for a sample missingness rate <2%, an SNP missingness rate <4%, and an SNP deviation from Hardy-Weinberg <10 -6 . Principal components were generated with the SNPRelate package. 16 
Phenotype Data
EHR diagnoses were based on phecodes (https://phewas. mc.vanderbilt.edu/), which are collections of related International Classification of Disease, Ninth Revision diagnosis codes. 17 Phecodes have been extensively validated for use in genetic studies. [18] [19] [20] For each phecode, cases are participants with ≥2 instances of the code appearing in their medical record. Control subjects were participants without the clinical phenotype or any closely related phecodes and whose decade of birth fell within the range of birth decades observed among cases. Any eMERGE site that had <10 cases for a given phecode was excluded for that phenotype.
Phenotypes that affected only a single sex were not included in these analyses. There were 1128 clinical phenotypes with ≥300 cases in the EHR data set that were used in the phenome-wide association study (PheWAS) analyses. Plasma protein levels in the MDCS were measured with SOMAscan technology (1.3k assay). Peripheral blood samples were collected in EDTA-treated tubes and assayed according to the manufacturer's protocol, as previously described. 7, 21 Fasting low-density lipoprotein (LDL) cholesterol (LDL-C) levels were measured, as previously described. 22 The prevalent atherosclerosis phenotype was defined as a focal thickening of the carotid intima-media >1.2 mm with an area of ≥10 mm 2 , as previously described.
Genome-Wide Association Study Summary Statistics
Summary statistics from published genome-wide association studies of plasma protein levels measured with the SOMAscan technology were used in these analyses, as described below.
Framingham Heart Study
Proteomic profiling (n=1129 proteins) was performed on peripheral blood samples among participants in the FHS Offspring cohort who attended the fifth examination (1991) (1992) (1993) (1994) (1995) with the SOMAscan single-stranded DNA aptamer-based platform (1.1k assay in FHS and 1.3k assay in MDCS). 7, 21 A total of 759 participants without In a traditional design (top), the biomarker and outcomes are measured in the same population, and either prospective or cross-sectional associations are explored.
In the genetics-based study design used in these analyses (bottom), genetic predictors of biomarker levels are constructed in 1 population. These predictors are then used to compute genetically predicted biomarker levels for each individual in a second genotyped population. Associations between the predicted biomarker levels and a large number of outcomes are then tested within the clinical population. SNP indicates single nucleotide polymorphism. 
Statistical Analysis
Validating Protein Predictors
An overview of validation and construction of genetic predictors of protein levels is presented in Figure 2 . There were 1112 proteins with summary statistics available in both the FHS (used as the discovery set) and KORA (used as the validation set) data sets. To define a set of validated genetic predictors of protein levels, SNPs exceeding each of 4 P-value selection thresholds (5×10 −8 , 5×10 −7 , 5×10 −6 , and 5×10 −5 ) were selected for each protein using the FHS set. The predictors based on lower thresholds incorporate additional SNPs with weaker associations and potentially capture a broader polygenic signal. At each selection threshold, a linkage disequilibrium-reduced (r 2 =0.2) set of SNPs with a minor allele frequency >5% that overlapped with the KORA set was selected with the use of a clumping algorithm. 24 To determine whether the SNPs at a given threshold predicted protein levels in KORA, we tested for consistency in the direction of the regression coefficients of the SNPs across data sets on the basis of an inverse-variance weighted average using methods previously described. 25 For each protein, we identified the SNP selection threshold that had the most significant association in the inverse-variance weighted average analysis and selected the ratio estimate and its P value from the inversevariance weighted average analysis. The association was considered significant if the inverse-variance weighted average P value was <0.01. This significance threshold was determined empirically by examining the direction of the ratio estimates across P values. For replicating proteins, the ratio estimate is expected to be positive. For proteins with P<0.01, 2 of 268 (0.7%) proteins had a negative ratio ( Figure I in the onlineonly Data Supplement). In contrast, 46% of proteins with values of P>0.01 had a negative ratio estimate, which is close to what would be expected by chance (50%).
PheWAS
A PheWAS analysis was performed for each of the 268 proteins. PheWASs test associations between a variable and a large collection of clinical diagnoses extracted from an EHR data set. 17, 19 Genetic predictors were constructed for each protein by selecting a linkage disequilibrium-reduced (r 2 =0.2) set of SNPs exceeding the best P value selection threshold identified in the validation step, Validating Protein Predictors. A new set of SNPs was selected because the SNP overlap between the FHS and the KORA and EHR data sets differed. SNPs and their weightings used to construct each protein predictor are shown in Table III in the online-only Data Supplement. For each predictor, the genetically predicted protein level among participants in the EHR population represented a weighted genetic risk score and was computed with the following equation: predicted level=∑[β i ×(number of reference alleles for SNP i )], where β i is the SNP effect size.
Multivariable logistic regression modeling, adjusting for 3 principal components, birth decade, sex and genotyping platform, was used to test associations with each PheWAS phenotype and predicted protein levels. The genetically predicted phenotype values were standardized to have an SD of 1, so odds ratios (ORs) reflect the risk per 1-SD increase in the genetically predicted biomarker value. A Benjamini-Hochberg false discovery rate adjustment was applied across all analyses to adjust for multiple testing. 26 PheWAS analyses used SAS version 9.3 (SAS Institute, Inc, Cary, NC).
To ascertain the contribution of SNPs located near the gene locus for the protein product, genetic predictors were also constructed using only SNPs located within 1 megabase of the transcription start and stop sites for the gene.
Validation Studies
For each protein, the proportion of phenotypic variation explained by the genetically predicted level was determined in the MDCS cohort by computing the partial Pearson correlation coefficient, with adjustment for age and sex, between the genetically predicted and measured levels of the protein.
The genetic predictors for all proteins associated with a clinical diagnosis related to elevated LDL-C levels (n=7 proteins), and atherosclerotic cardiovascular diseases (peripheral vascular disease, stroke, carotid stenosis, and coronary heart disease; n=6 proteins) in the discovery EHR cohort were validated in the MDCS cohort by testing associations with either baseline LDL levels (n=615 subjects) or the carotid plaque phenotype (n=168). LDL differences were estimated with linear regression, and ORs for the presence of carotid atherosclerosis were estimated with logistic regression models. All models analyzed log-transformed protein levels as the independent variable and adjusted for age, sex, and plate. LDL changes and ORs are per 1-SD increase in the log-transformed protein level. Associations with a Bonferroni-adjusted value of P<(0.05/7=0.0071) for LDL and P<(0.05/6=0.008) for atherosclerosis were considered significant. CLC1B (C-type lectin domain family 1 member B) and PDGFR-β (platelet-derived growth factor receptor-β) associations were also examined with the use of a logistic model that further adjusted for body mass index, fasting glucose levels, hypertension status, smoking status, LDL levels, and C-reactive protein levels.
Study Approval
The eMERGE study was approved by the Institutional Review Board at each site. 8 The study protocols were approved by the Institutional Review Board of Boston University Medical Center, Beth Israel Deaconess Medical Center, and Lund University, Sweden, and all participants provided written informed consent.
RESULTS
We used a 2-step approach to identify novel biomarkerdisease associations (Figure 1 ). We constructed genetic predictors for each of 268 plasma proteins that were measured in the FHS Offspring cohort and successfully validated in the KORA data set (Figure 2) . In cross-validation analyses using the MDCS cohort, the median proportion of the variability in plasma protein levels explained by the predictors was 0.08 (interquartile range, 0.04-0.22; Figure 3A and Table IV in the online-only Data Supplement). Genetically predicted protein levels were then imputed into the EHR population (n=41 288), and associations were tested with each of 1128 clinical phenotypes. There were 223 associations among 55 proteins and 89 clinical diagnoses that were significant For each protein, up to 4 predictors are created by incorporating single nucleotide polymorphisms (SNPs) meeting increasingly higher P value thresholds. Each predictor is then tested for validation in the Cooperative Health Research in the Region of Augsburg (KORA) data set with an inverse variance weighted average (IVWA) association approach. The predictor with the lowest IVWA association P value is then selected for further analysis.
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at a false discovery rate q<0.1 ( Figure 3B and Table V in the online-only Data Supplement). A number of proteins were associated with multiple similar phenotypes. For instance, the protein coagulation factor XI (F11) was associated with 4 diagnoses related to venous thrombosis ( Figure 3C and 3D) . Among the 55 proteins with associations, 16 (22.6%; basal cell adhesion molecule, platelet glycoprotein 4, F11, CD209 molecule, endoglin, insulin receptor, protein jagged-1, hepatocyte growth factor receptor, OX-2 membrane glycoprotein, P-selectin, soluble E-selectin, carbohydrate sulfotransferase 15, soluble tyrosine-protein kinase receptor (Tie-1), vascular endothelial growth factor receptor 2, vascular endothelial growth factor receptor 3, von Willebrand Factor) were associated with a thrombosis phenotype ( Figure 3E and Table VI in the online-only Data Supplement). For all but 4 of these proteins (F11, CD209 molecule, ST4S6, soluble Tie-1), the association signal was driven by SNPs comprising the genetic predictor that were located near the ABO gene locus. These findings are consistent with prior observations that levels for a large number of proteins are regulated by the ABO gene. 5, 27 Other phenotype categories with multiple protein associations included autoimmune disorders (soluble mitogen-activated protein kinase [MAPK] overlapping kinase, cystatin-SN, complement C4-A, hemojuvelin, cation-independent mannose-6-phosphate receptor, MICA [major histocompatibility complex class I polypeptide-related sequence A], major histocompatibility complex class I polypeptide-related sequence B, neutrophil collagenase), atherosclerotic phenotypes (CLC1B, MICA, 
proprotein convertase subtilisin/kexin type 7, PDGFR-β, soluble E-selectin, vascular endothelial growth factor receptor 2), lipid disorders (apolipoprotein E [apo E] isoforms, catalase, interleukin 27, granulin), and dementia (soluble Tie-1 and apo E isoforms; Figure 3E ).
To validate lead predicted biomarker associations, we tested the association between directly measured plasma protein levels and validation phenotypes in the MDCS cohort. We tested all proteins associated with either a diagnosis of elevated cholesterol levels (n=7 proteins) or an atherosclerosis phenotype (n=6 proteins). The genetic predictors for the 7 cholesterol-associated proteins accounted for 3% (median; interquartile range, 1%-7%) of the variance in the measured protein levels in the MDCS cohort (Table VII in the online-only Data Supplement). Four of the 7 proteins were apo E isoforms. Directly measured levels of each isoform were significantly associated with LDL-C levels in the MDCS cohort and had a consistent direction of association as the genetic association (Table 1 ). There was no epidemiological association with LDL-C for the other 3 proteins (catalase, interleukin-27, granulin).
The 6 proteins with atherosclerosis associations involved peripheral vascular disease (CLC1B, proprotein convertase subtilisin/kexin type 7) and cerebrovascular disease (MICA, PDGFR-β, soluble E-selectin, vascular endothelial growth factor receptor 2; Table 2 ). The genetic predictors for these proteins accounted for 27% (median; interquartile range, 7%-48%) of the variance in the measured levels in the MDCS cohort (Table VII in the online-only Data Supplement). We tested these proteins for an association with the presence of carotid plaque in the MDCS cohort (Table 3 ). For 5 of the 6 proteins, the direction of association was consistent between the discovery and validation cohorts (Figure 4) . Two of the 6 lead proteins met a conservative, Bonferroni-adjusted level of significance (P<0.008). Measured CLC1B levels were associated with an increased risk of carotid plaque in MDCS (OR, 1.31 per 1-SD increment in biomarker level; 95% CI, 1.08-1.58, P=0.006), consistent with the direction of effect found in the discovery cohort for the predicted levels (OR, 1.14; 95% CI, 1.09-1.18; P=3.0×10 −9 ). Similarly, we found an inverse association between measured plasma PDGFR-β levels and carotid plaque in MDCS (OR, 0.79; 95% CI, 0.66-0.94; P=0.008), consistent with the association of predicted PDGFR-β and acute stroke in the EHR cohort (OR, 0.88; 95% CI, 0.83-0.94; P=4.6×10 −5 ). The carotid plaque associations for CLC1B and PDGFR-β persisted despite further adjustment for established atherosclerosis risk factors and high-sensitivity C-reactive protein levels. The multivariable-adjusted ORs per 1-SD increment in CLC1B and PDGFR-β were 1.27 (95% CI, 1.05-1.54; P=0.015) and 0.81 (95% CI, 0.67-0.97; P=0.02), respectively. The model C statistic increased from 0.68 to 0.69 with the addition of each protein level as a covariate.
DISCUSSION
We used a virtual proteomic approach to identify novel biomarker-disease associations in a large (>40 000 individuals) clinical data set. Because direct measurement of >1000 proteins in this many individuals would be impractical, we leveraged genomic data to construct predicted biomarker levels for each individual and identified clinical associations with 55 proteins. We selected candidate associations related to hyperlipidemia and atherosclerotic cardiovascular disease for direct validation in an epidemiological cohort and demonstrated significant associations between directly measured protein levels and LDL-C (apo E) and carotid atherosclerosis (CLC1B and PDGFR-β). †Electronic health records genetic association based on logistic regression analyses for an association with a diagnosis of hyperlipidemia (n=8511 cases and 13 436 control subjects) with adjustment for birth year, sex, Electronic Medical Records and Genomics (eMERGE) site, genotyping platform, and 3 principal components.
‡MDCS (Malmö Diet and Cancer Study) epidemiological validation showing the change in low-density lipoprotein cholesterol levels based on a linear regression model adjusted for age, sex, and plate.
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There are multiple challenges related to identifying and validating novel disease biomarkers using standard epidemiological approaches. These include logistical, throughput, cost, and resource challenges inherent in measuring a candidate biomarker in large study populations. Proteomic discovery in large EHRbased cohorts is further complicated by sample-processing challenges, particularly time to appropriate storage, that do not affect genetic analyses. These limitations may compel investigators to rely on candidate biomarker approaches that have less potential for discovery. Traditional biomarker study designs are also limited by the fact that a biomarker can be tested only against other phenotypes measured in the same cohort and cannot be rapidly repurposed for use in other populations. We evaluated an approach designed to overcome these limitations by using genetic predictors as surrogates for circulating biomarkers. This approach is similar to the PrediXcan and transcriptomewide association study methods that have been used to associate RNA expression levels with diseases. 28, 29 The utility of the PrediXcan and transcriptome-wide association study approaches lends general support to the strategy outlined in the present investigation. One distinction, and a potential advantage of the virtual proteomics method, is the ability to validate the genetic findings with directly measured levels. This approach enabled us to test for biomarker associations in a significantly larger population than the population in which the biomarker was actually measured and to screen the biomarker against a large number of clinical diagnoses. Hence, we identified associations with phenotypes not ascertained in the original cohort.
For these analyses, our candidate biomarkers were plasma protein levels. One advantage of protein biomarkers is that their levels are modulated by common SNP variants, thereby making them amenable to a genetic-based study design. 5 A second advantage is that an association potentially highlights a mechanism of disease because the protein may be a mediator of the disease process. We note that a virtual proteomics approach cannot detect all of the associations that would be captured with direct proteomic measurements on the same study population. The intent of the approach is to enable protein discovery in study populations not currently accessible to a traditional approach. Some associations have immediate face-value interpretability. For instance, we observed that higher genetically predicted levels of the blood coagulation factor F11 were associated with an increased risk of deep vein thrombosis, consistent with previously reported associations between F11 levels and venous thrombosis. 30 Apo E and its isoforms were associated with hyperlipidemia and dementia, consistent with the known biology of this protein. 31 A third advantage is that proteomics technologies are rapidly advancing, and increasingly large numbers of proteins can be measured by these technologies. Hence, there is great potential for ongoing novel biomarker discovery in this domain. Last, predicted biomarker associations can be validated with biospecimens obtained from conventional clinical or epidemiological studies. CLC1B indicates C-type lectin domain family 1 member B; MICA, major histocompatibility complex class I polypeptide-related sequence A; PCSK7, proprotein convertase subtilisin/kexin type 7; PDGFR-β, platelet-derived growth factor receptor-β; sE-selectin, soluble E-selectin, and VEGF-sR2, vascular endothelial growth factor receptor 2.
*Indicates whether the association was significant (P<0.01) when analyses were limited to single nucleotide polymorphisms located within 1 Mb of the gene locus.
†Based on logistic regression analyses adjusted for birth year, sex, Electronic Medical Records and Genomics (eMERGE) site, genotyping platform, and 3 principal components. CLC1B indicates C-type lectin domain family 1 member B; MICA, major histocompatibility complex class I polypeptide-related sequence A; PCSK7, proprotein convertase subtilisin/kexin type 7; PDGFR-β, platelet-derived growth factor receptor-β; sE-selectin, soluble E-selectin, and VEGF-sR2, vascular endothelial growth factor receptor 2.
*From multivariable logistic regression models adjusted for age, sex, and plate.
Circulation. 
Although the discovery phase of our approach uses a genetic association study, it is not a mendelian randomization, a study design that seeks to infer causality between a biomarker and outcome. 32 Mendelian randomization requires explicit knowledge and modeling of known mediators and risk factors associated with a biomarker and a disease. The primary goal of this study was to identify new protein biomarkers, not to establish causal relationships. For a biomarker to be an effective predictor of an outcome of interest, its level must vary with respect to risk of that outcome. Hence, we constructed genetic predictors designed to capture genetic signals modulating biomarker levels. However, a significant association with a genetic predictor can occur in situations in which the biomarker does not vary with respect to the risk of the outcome. For instance, if an SNP in the predictor tags a pleiotropic genetic locus that is associated with an outcome through a mechanism unrelated to that regulating biomarker levels, it could give rise to a false-positive association with the outcome. 33 The definitive approach to discriminate these possibilities is to directly test the candidate association between the measured biomarker level and outcome in an independent cohort, as done in the present study.
We selected hyperlipidemia and atherosclerosis traits for the independent validation. Among the hyperlipidemia associations, there was strong replication among the apo E isoforms, consistent with previous epidemiological studies examining apo E levels measured with the SOMAscan platform. 7 The genetic associations for the apo E isoforms were driven by SNPs located near the apo E gene locus. In contrast, for the proteins that did not have an epidemiological replication, the genetic association was driven by transacting SNPs. Among these, granulin (GRN) is perhaps the most interesting. The genetic association we observed was driven by SNPs in chromosome 1 located near the CELSR2-PSRC1-MYBPHL-SORT1 gene loci that have been previously reported. 34, 35 Prior protein-wide association studies have linked GRN with coronary artery disease through SNPs located at this gene locus, 5, 27 and genome-wide association studies have identified SNPs with strong associations to LDL-C levels in this same region. 36 Mutations in GRN are associated with the neurodegenerative disease frontotemporal dementia. However, GRN does not have a known role in LDL homeostasis. The genetic association between GRN and hyperlipidemia is likely explained by SORT1, which is the main neuronal receptor for GRN. SORT1 also reduces LDL levels by increasing uptake and catabolism of LDL. 37 Thus, although genetic variation may influence SORT1 activity in these 2 different contexts, this does not translate into an epidemiological association that supports the observation that GRN may be an LDL-C biomarker.
For proteins with an association with an atherosclerotic disease, we tested their association with the presence of carotid plaque, a well-established marker of atherosclerotic disease burden. Among 6 candidate associations, 2 (PDGFR-β and CLC1B) met the conservative Bonferroni significance threshold. The genetic associations for both of these proteins were driven by cis-acting SNPs, which may also account for the higher proportion of variability explained for the protein levels.
Lower serum levels of PDGFR-β were associated with an increased risk of acute stroke and the presence of carotid plaques in our analyses. PDGFR-β is a tyrosine kinase cell-surface receptor involved in development and signaling in a range of contexts. The contribution of PDGFR-β to the formation and promotion of atherosclerotic plaque formation has been described in both in vitro and in vivo studies in model systems. During development, this receptor is involved in the recruitment and migration of pericytes and smooth muscle cells to endothelial cells. 38 Inhibition of this receptor in apo E-deficient mice markedly decreased atherosclerotic lesion size in the aorta 39 , whereas constitutive activation of signaling promotes leukocyte accumulation in the adventitia and media of arteries. 40 In human cadaver studies, PDGFR-β was expressed mostly in smooth muscle cells. 41 Macrophages, which are important mediators of atherosclerotic plaque formation, also secrete ligands that activate this receptor. 42 On the basis of the known biology of this receptor, the inverse association between PDGFR-β levels in plasma and atherosclerosis risk that we observed suggests that the regulation of receptor levels in plasma may differ from regulation at the site of an atherosclerotic lesion. Consistent with this, PDGFRB mRNA levels are low in whole-blood samples but high in the aorta and coronary arteries. 43 It may also be possible that our observed genetic association with acute stroke in the EHR data set is related to Odds ratios and 95% CIs for associations between the genetic predictors and the indicated phenome-wide association study clinical diagnoses in the EHR data set (left) and between measured levels of the protein and carotid atherosclerosis (right). An asterisk denotes that the association in MDCS was significant. CLC1B indicates C-type lectin domain family 1 member B; MICA, major histocompatibility complex class I polypeptide-related sequence A; PCSK7, proprotein convertase subtilisin/kexin type 7; PDGFR-β, platelet-derived growth factor receptor-β; sE-selectin, soluble E-selectin; and VEGF-sR2, vascular endothelial growth factor receptor 2.
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Circulation. 44 Thus, low plasma levels of PDGFR-β may be promoting arterial occlusion through a direct thrombotic mechanism.
Increased predicted plasma concentration of CLC1B was associated with peripheral vascular disease and epidemiologically associated with carotid plaque formation. CLC1B is a cell-surface receptor initially identified on platelets, where it was found to promote aggregation in response to the snake venom rhodocytin. 45 As a platelet receptor, it was also shown to mediate blood and lymphatic vessel separation during development, to modulate lymphatic endothelial cell signaling, and to promote lymph node development and maintenance. 46 Circulating neutrophils also express CLC1B, which can be activated to promote phagocytosis and production of proinflammatory cytokines. 47 In addition, the receptor is expressed on other myeloid cells and can modulate inflammatory responses. 48 Although the receptor can be cleaved to generate a soluble product, regulators of this process have not been identified. A specific role related to atherosclerosis has not been defined.
Another protein, MICA, was genetically associated with a diagnosis of carotid stenosis, but its protein levels were not associated with carotid plaque in the validation set. The MICA genetic predictor was also associated with a diagnosis of psoriasis, an inflammatory condition associated with increased rates of vascular disease. 49 Hence, it is possible that the EHR data set may capture atherosclerotic disease mechanisms not represented in the validation cohort and could explain the failure to replicate that association.
There are several limitations to this study. Although the FHS Offspring cohort represents one of the larger studies of SOMAscan-measured plasma proteins to date, larger sample sizes will facilitate the development of stronger genetic predictors, conferring more power to identify disease associations. The SOMAscan platform also contains a discrete sampling of proteins, so many candidate protein biomarkers are not interrogated by this study. Plasma proteins with weak genetic effects or levels that fluctuate abruptly in response to acute events (eg, troponin levels in myocardial infarction) are not well suited to the discovery approaches used here. Furthermore, there is low power to detect associations with many phenotypes for predictors that account for only small amounts of the phenotypic variance. Inaccurate predictors will contribute to the rate of false positives. The PheWAS phenotypes are based on EHR billing codes rather than a systematic ascertainment of a diagnosis, which can lead to misclassification causing both false-positive and false-negative associations. 50 These considerations highlight the importance of prospective epidemiological and molecular studies using well-curated phenotypes to validate candidate associations. Epitope effects (ie, missense SNPs that alter the epitope for the DNA aptamer, causing reduced detection by the Somalogic assay) may create associations between genotypes and proteins that do not represent variation in the level of the protein. If the genetic variant creates an assay-related alteration rather than a functional change, it should not contribute to a clinical phenotype and should not lead to false-positive results with regard to clinical end points. On the other hand, if these missense variants are also associated with a clinical phenotype, then the implied biomarker association may be a false positive. Validating candidate associations with an independent data set and testing for direct associations between the measured protein level and the phenotype should mitigate the risk of spurious associations caused by epitope effects. In specific support of the PDGFR-β and CLC1B findings, prior studies analyzing binding with homologous proteins for these SOMAscan aptamers did not observe cross-reactivity, 27 and the SNP variants underlying the association with the genetic predictors are located at the gene locus. However, de novo measurements of these proteins with antibody-based assays would provide further independent validation. To ensure highquality findings, we reported only associations for predictors that were cross-validated in the KORA cohort. Hence, we did not report clinical associations for some proteins with strong SNP associations in the discovery set that did not cross-validate. Extension of these approaches and our findings to other ancestral groups is also needed to define their broader utility. Finally, our validation cohort was moderate in size, and the validation phenotype was not identical to the clinical phenotypes, which can lead to false-negative associations. Although these limitations may have decreased the number of associations that could be identified and validated, the confirmed findings provide support for this approach. Studies in large, well-characterized cohorts are necessary to further refine and validate the use of this approach for discovery.
CONCLUSIONS
We identified and validated 2 biomarkers of atherosclerotic disease using a virtual proteomic approach applied to large EHR data sets. The biomarkers include 1 (PDGFR-β) with strong supporting biological evidence and 1 (CLC1B) that may represent a novel disease mechanism. This discovery-oriented study design is efficient and rapid and overcomes important limitations inherent to traditional approaches to biomarker discovery. This approach may accelerate and broaden the process of biomarker discovery.
